The safety database for an anti-hypertensive drug consists of the following:
* 461 patients exposed for three months
* 343 patients exposed for six months
* 112 patients exposed for nine months
* 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?

• A.3.000 total patient exposures
• B.500 patients for three months
• C.100 patients for 12 months
• D.200 patients for nine months

Comment: *

Name: *

Email: *

Verification: *

In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?

• A.Product registration
• B.Product stability
• C.Product formulation
• D.Product requirements

Comment: *

Name: *

Email: *

Verification: *

Company X acquires Company Y.
Both companies produce pharmaceuticals distributed globally. A regulatory authority requires that all labeling for Company Y's products be converted to Company X within three months. The regulatory affairs professional at
Company X concludes that it is not feasible to meet this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the situation?

• A.Submit as many labeling conversion applications as possible within the time frame and request an extension for the remaining ones.
• B.Request additional resources from senior management in order to complete the labeling conversion within the time frame given by the regulatory authority.
• C.Convene an urgent meeting with internal stakeholders to inform them of the regulatory authority requirement and assign responsibilities.
• D.Develop a plan of action with tasks, timelines, and responsibilities and request an extension period from the regulatory authority.

Comment: *

Name: *

Email: *

Verification: *

Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your company?

• A.Develop documented procedures for regulatory compliance processes and train personnel.
• B.Train all new employees on regulatory compliance processes and assign a mentor to them.
• C.Document any failure to follow regulatory compliance processes in employee performance reviews.
• D.Train employees on all regulatory compliance processes using state-of-the-art systems.

Comment: *

Name: *

Email: *

Verification: *

During face-to-face meetings with the regulatory authority to address submission issues, what is the BEST choice for the number of company representatives who should attend?

• A.All senior management from the main office
• B.As many as required by international standards
• C.The minimum number of attendees necessary to address the issues
• D.As many as government attendees

Comment: *

Name: *

Email: *

Verification: *